<DOC>
	<DOC>NCT01861522</DOC>
	<brief_summary>The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis and to investigate safety of TAU-284.</brief_summary>
	<brief_title>The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis</brief_title>
	<detailed_description>This is a randomized, double-blind, placebo-controlled, 2-arm parallel-group comparative study to confirm the superiority of TAU-284 over placebo after two weeks of administration of TAU-284 (20 mg/day) or placebo to pediatric patients with perennial allergic rhinitis, with "the change from baseline in total nasal symptom score (total score for the three major nasal symptoms [sneezing, rhinorrhea, and nasal congestion])" as the primary endpoint; and to investigate safety of TAU-284.</detailed_description>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<criteria>Patients aged between 7 and 15 years Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic criteria Patients with a mean rhinorrhea score and a mean sneezing score of at least 2 on the basis of symptoms recorded in the nasal allergy diary during the observation period etc. Patients with vasomotor rhinitis or eosinophilic rhinitis Patients who have concurrent nasal disease that may affect the efficacy of TAU284 Patients with a history of any of the nasal surgical procedures Patients who have a positive result for pollen antigens which are dispersed during the study period Patients who have a positive result for dog dander or cat dander antigen and have a chance to touch dogs or cats. Patients with current or previous history of drug allergy Patients who concurrently have renal function abnormalities that may cause safety problems etc.</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>TAU-284</keyword>
	<keyword>Bepotastine besilate</keyword>
	<keyword>Histamine H1 receptor antagonists</keyword>
	<keyword>children</keyword>
</DOC>